Physician profile
Joseph Ali
NPI 1417238403
$5,726.07
in general payments reported to CMS, 2019-2025
22 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 88% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $1,207 · 2023: $1,455 · 2024: $808 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,719 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.70 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,247.39 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $520.45 | 2021-2025 | Caplyta |
| Lundbeck LLC | $381.98 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $350.39 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $342.57 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $339.94 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $297.45 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $243.61 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $218.49 | 2022-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $190.75 | 2023-2025 | Auvelity, Sunosi |
| Sunovion Pharmaceuticals INC. | $142.74 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $66.42 | 2022 | |
| Avanir Pharmaceuticals, INC. | $57.28 | 2022 | |
| Eisai INC. | $52.63 | 2021 | |
| Bausch Health US, LLC | $50.04 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $49.57 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $48.43 | 2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $46.46 | 2021-2025 | Fanapt |
| Almatica Pharma LLC | $28.46 | 2024 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $21.25 | 2023 | |
| Idorsia Pharmaceuticals US INC | $16.31 | 2023 | Quviviq |
| Biogen, INC. | $13.46 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.